I realize this is nitpicking a minor point in your comment, but I don't agree with your characterization of RCTs in medical research as being primarily constrained by laws and regulations. Any time I've discussed research on human subjects with doctors doing that research, the discussion of what is and is not an acceptable experiment has always been primarily driven by the risks of harm to the people involved in the study. Any time the law comes up, it's usually because the law
requires an RCT in a specific setting, as opposed to preventing it (e.g. drug trials). (Of course in the setting of starting a company based on some medical product, the situation may be quite different.)
Biologists, if not data scientists, are used to considering indirect evidence for causality. It's why we sometimes accept studies performed in other organisms as evidence for biology in humans; it's why we sometimes accept research performed on post-mortem human tissue as being representative of the biology of living humans; to name but a few examples. A big part of a compelling high-impact biology (or bioinformatics) paper is often the innovative ways that one comes up to show causality when a direct RCT is not feasible, and papers are frequently rejected because they don't to the follow-up experiments required to show causality.